Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REC-01-002: High-purity mesenchymal stem cell transplantation in pediatric hypophosphatasia
jRCT2053250167Phase 1Not yet recruiting
- Sponsor
- PuREC
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dutogliptin in hypophosphatasia (HPP), sponsored by PuREC. Primary endpoint: Safety (adverse events and malfunctions). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
dutogliptin
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on jRCT2053250167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053250167.